This COVID-19 Shot is No Longer Available in the United States

The Centers for Disease Control & Prevention (CDC) announced that the Johnson & Johnson COVID-19 shot is no longer available in the United States.

All remaining doses of the experimental shot expired on May 7th, 2023 and authorities had to dispose of them.

Johnson & Johnson COVID-19 Vaccine Becomes Unavailable In US https://t.co/A1gZKvBbyC

— zerohedge (@zerohedge) May 17, 2023

All remaining Johnson & Johnson vaccine doses have expired and the US government has ceased purchasing it. Be sure to dispose of any remaining doses in accordance with local, state, and federal regulations.https://t.co/4M5rIwZU3T

— Facts Matter (@FactsMatterRB) May 18, 2023

From the CDC:

Janssen COVID-19 Vaccine is no longer available in the U.S. All remaining U.S. government stock of Janssen COVID-19 Vaccine expired May 7, 2023. Dispose of any remaining Janssen COVID-19 Vaccine in accordance with local, state, and federal regulations.

People ages 18 years and older who received 1 dose of Janssen COVID-19 Vaccine should be considered to have received a single-dose Janssen primary series.

People ages 18 years and older who received 1 or 2 Janssen COVID-19 Vaccine dose are recommended to receive 1 bivalent mRNA dose (Moderna or Pfizer-BioNTech) at least 2 months after completion of the previous dose.

ADVERTISEMENT

The CDC and Johnson & Johnson did not respond to requests for comment, according to reports.

From The Epoch Times via Zero Hedge:

U.S. regulators first cleared the jab in February 2021, giving Americans an alternative to the messenger RNA-based Moderna and Pfizer COVID-19 vaccines. Johnson & Johnson’s vaccine became popular in part because it’s only a single dose. The messenger RNA vaccines each have a primary series of two doses.

But uptake slowed after U.S. authorities paused recommending the vaccine because of concerns about a reported link to a combination of blood clotting and low platelet levels, a condition called thrombosis with thrombocytopenia syndrome (TTS) that can cause death. About 15 percent of the post-vaccination TTS cases have been fatal.

Regulators limited the availability of the vaccine in 2022 because experts determined it caused TTS.

Since March, recipients have also been warned that they face an increased risk of myocarditis, or heart inflammation, and a related condition called pericarditis. All four COVID-19 vaccines authorized in the United States present an increased risk of myocarditis, primarily for young males.

As of May 11, 19 million Johnson & Johnson shots have been administered, compared to more than 403 million Pfizer shots, more than 252 million Moderna shots, and about 89,000 Novavax shots, according to data reported to the CDC.

The FDA issued this release in May 2022 regarding the Johnson & Johnson COVID-19 shot.

Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.

Key Points:

ADVERTISEMENT

• After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine.
• The FDA has determined that the known and potential benefits of the vaccine for the prevention of COVID-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and for individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.
• The Fact Sheet for Healthcare Providers Administering Vaccine now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS. Additionally, information on the revision to the authorized use of the vaccine and updated information on this risk of blood clots with low levels of blood platelets has been added to the Fact Sheet for Recipients and Caregivers.